Assessment of the risk of zoonotic infections in prisons in french guiana
NCT ID NCT07808775
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
The prison system in French Guiana is characterized by severe overcrowding, high levels of promiscuity, poor sanitary conditions, and the documented presence of potential reservoirs or vectors of zoonotic diseases, particularly swallows and rodents. In French Guiana, several zoonotic diseases have a high incidence or are of particular public health significance, including Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis. Despite this context, the risk of zoonotic diseases in prisons remains poorly documented, even though endemic and epidemic circulation of Q fever has already been described at the French Guiana correctional facility. This study aims to document this risk in a systematic and prospective manner. The main objective is to assess the prevalence of zoonotic infections (Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis) among inmates at the French Guiana Correctional Facility in 2026-2027. The other objectives are : * To measure the seroprevalence of zoonotic infections among new arrivals at the French Guiana correctional facility; * To identify individual risk factors, both within and outside the prison, for acquiring zoonotic infections; * To analyze the results in relation to bioclimatic data (wind direction, humidity, precipitation, temperature) The expected benefits will aim to objectively assess the risk of zoonotic diseases within the French Guiana correctional facility, to improve understanding of zoonoses in prison settings, to guide the implementation of appropriate prevention and screening measures, and to contribute to improving health conditions in detention. It should also strengthen cooperation between health and justice officials as part of an integrated approach to the prevention and management of infectious diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 450 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults above 18 years old, incarcerated and housed at the French Guiana Correctional Facility for 15 days or less, from september 2026 to september 2028
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult aged 18 or older * Incarcerated and housed at the French Guiana Correctional Facility for 15 days or less. Exclusion Criteria: * Refusing to participate in the study * Pregnant women * Had already participated in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chagas disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier de Cayenne
Cayenne, French Guiana, 97300, French Guiana
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A first-in-human, randomized, subject blinded, placebo controlled, single and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of LXE408 in healthy subjects
- Can a new pill tame fungal infections when standard drugs fail?
- Can we predict who will suffer severe leptospirosis?
- Could leptospirosis leave lasting damage? a new study investigates
- Campus sweep: rapid chagas tests could uncover thousands of hidden cases
- Scientists investigate immune system failures in leptospirosis to find better treatments